Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 18, 2026 | June 23, 2026 |
| JOHNSON & JOHNSONJNJ · Entity 2722 | VP, Human Resources | December 31, 2009 | January 05, 2010 |
| Prime Medicine, Inc.PRME · Entity 5281 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 10,284 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 10,284 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,927 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18 | Direct | 14,950 |
Reported balance
After 2026-06-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. |
| Common stockSEC Table I · non-derivative | IndirectBy Foster Family Revocable Trust | 2,200 |
Reported balance
Holding disclosure · report date 2026-06-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,200 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
JOHNSON & JOHNSON
Report date December 31, 2009 · Filed January 05, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | IndirectJohnson & Johnson Stock Fund under the 401(k) Savings Plan | 1,181 |
Reported balance
After 2009-12-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2009-12-31 · Other · Acquired 34 · Balance 1,181 F2: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (12/31/2009). |
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,998 |
Reported balance
After 2009-12-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2009-12-31 · Grant · Acquired 45 · Balance 5,998 F4: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2009 at $64.78 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time. |
| Common StockSEC Table I · non-derivative | Direct | 4,583 |
Reported balance
Holding disclosure · report date 2009-12-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,583 F1: Includes 819 shares held under Issuer's Dividend Reinvestment Program. |
| CommonSEC Table I · non-derivative | IndirectESOP under the 401(k) Savings Plan | 33 |
Reported balance
Holding disclosure · report date 2009-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 33 F3: Shares held by ESOP under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (12/31/2009). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 819 shares held under Issuer's Dividend Reinvestment Program.
F2: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (12/31/2009).
F3: Shares held by ESOP under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (12/31/2009).
F4: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2009 at $64.78 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time.
Prime Medicine, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2036-06-05 | Direct | 75,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 75,000 · Balance 75,000 F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2019 Filed May 31, 2019 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-033618 · doc4.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033618 · doc4.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878 Underlying: Common stock · 1,878 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 8,919 | $0.00 Strike: $47.91 | $0.00 |
DisclosureSEC source: 0001209191-19-033618 · doc4.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,919 Underlying: Common stock · 8,919 shares Expires 2029-05-29 F2 · derivative.exercise_date: This option was granted on May 29, 2019. The shares underlying this option vest as to 100% of the underlying shares on May 29, 2020. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $50.73 | $0.00 |
DisclosureSEC source: 0001209191-18-038277 · doc4.xml · derivative · entry 5 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 9,000 shares Expires 2027-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 839 | $94.30 | $79,117.70 |
DisclosureSEC source: 0001209191-18-038277 · doc4.xml · nonDerivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $94.21 to $94.63. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 5,980 | $93.78 | $560,804.40 |
DisclosureSEC source: 0001209191-18-038277 · doc4.xml · nonDerivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,039 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $93.15 to $94.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,181 | $92.62 | $202,004.22 |
DisclosureSEC source: 0001209191-18-038277 · doc4.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,019 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $92.14 to $93.11. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 9,000 | $50.73 | $456,570.00 |
DisclosureSEC source: 0001209191-18-038277 · doc4.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:17 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035041 · doc4.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:17 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 5,700 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001209191-18-035041 · doc4.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 20:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 6,800 | $0.00 Strike: $47.33 | $0.00 |
DisclosureSEC source: 0001209191-18-021060 · doc4.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 6,800 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option was granted on June 21, 2016. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2017. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 20:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 6,800 | $81.97 | $557,396.00 |
DisclosureSEC source: 0001209191-18-021060 · doc4.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.53 to $82.52. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 20:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 6,800 | $47.33 | $321,844.00 |
DisclosureSEC source: 0001209191-18-021060 · doc4.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 21:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 2,200 | $0.00 Strike: $47.33 | $0.00 |
DisclosureSEC source: 0001209191-18-014455 · doc4.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common stock · 2,200 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on June 21, 2016. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2017. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 21:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,200 | $47.33 | $104,126.00 |
DisclosureSEC source: 0001209191-18-014455 · doc4.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $50.73 | $0.00 |
DisclosureSEC source: 0001209191-17-040190 · doc4.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common stock · 9,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018. Read SEC document |
| December 31, 2009 Filed Jan 5, 2010 21:18 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPhantom Stock Units · Derivative | 45 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-10-000001 · edgar.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,998 Underlying: Common Stock · 45 shares Expires not disclosed F4 · derivative.exercise_price: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2009 at $64.78 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time. F4 · derivative.exercise_date: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2009 at $64.78 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time. F4 · derivative.expiration_date: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2009 at $64.78 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time. Read SEC document |
| December 31, 2009 Filed Jan 5, 2010 21:18 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 34 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-10-000001 · edgar.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Stock Fund under the 401(k) Savings Plan Disclosed balance after: 1,181 F2 · security: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (12/31/2009). F2 · price: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (12/31/2009). Read SEC document |
| December 10, 2009 Filed Dec 11, 2009 19:45 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 71,992 | $0.00 Strike: $58.34 | $0.00 |
DisclosureSEC source: 0000200406-09-000142 · edgar.xml · derivative · entry 10 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,992 shares Expires 2016-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Awarded under Issuer's Stock Option Plan and exercisable in full starting three years from date of grant. Read SEC document |
| December 10, 2009 Filed Dec 11, 2009 19:45 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $53.93 | $0.00 |
DisclosureSEC source: 0000200406-09-000142 · edgar.xml · derivative · entry 9 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,500 shares Expires 2014-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Awarded under Issuer's Stock Option Plan and exercisable in full starting three years from date of grant. Read SEC document |
| December 10, 2009 Filed Dec 11, 2009 19:45 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 13,250 | $0.00 Strike: $53.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000142 · edgar.xml · derivative · entry 8 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,250 shares Expires 2013-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Awarded under Issuer's Stock Option Plan and exercisable in full starting three years from date of grant. Read SEC document |
| December 10, 2009 Filed Dec 11, 2009 19:45 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | SaleCommon Stock | 96,742 | $64.76 | $6,265,011.92 |
DisclosureSEC source: 0000200406-09-000142 · edgar.xml · nonDerivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,583 F2 · price: This transaction was executed in multiple trades at prices ranging from $64.68 to $64.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2009 Filed Dec 11, 2009 19:45 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 71,992 | $58.34 | $4,200,013.28 |
DisclosureSEC source: 0000200406-09-000142 · edgar.xml · nonDerivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2009 Filed Dec 11, 2009 19:45 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 11,500 | $53.93 | $620,195.00 |
DisclosureSEC source: 0000200406-09-000142 · edgar.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2009 Filed Dec 11, 2009 19:45 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon | 13,250 | $53.00 | $702,250.00 |
DisclosureSEC source: 0000200406-09-000142 · edgar.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Includes 819 shares held under Issuer's Dividend Reinvestment Program. Read SEC document |
| November 30, 2009 Filed Dec 11, 2009 19:45 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 8 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000142 · edgar.xml · nonDerivative · entry 5 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Stock Fund under the 401(k) Savings Plan Disclosed balance after: 1,147 F3 · security: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (11/30/2009). F3 · price: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (11/30/2009). Read SEC document |
| September 30, 2009 Filed Oct 2, 2009 16:57 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPhantom Stock Units · Derivative | 48 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000111 · edgar.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,953 Underlying: Common Stock · 48 shares Expires not disclosed F4 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F5 · derivative.exercise_date: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on September 30, 2009 at $61.15 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time. F5 · derivative.expiration_date: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on September 30, 2009 at $61.15 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time. Read SEC document |
| September 30, 2009 Filed Oct 2, 2009 16:57 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 9 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000111 · edgar.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Stock Fund under the 401(k) Savings Plan Disclosed balance after: 1,139 F2 · security: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (09/30/2009). F2 · price: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (09/30/2009). Read SEC document |
| June 30, 2009 Filed Jul 2, 2009 19:28 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPhantom Stock Units · Derivative | 51 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000082 · edgar.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,905 Underlying: Common Stock · 51 shares Expires not disclosed F5 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F4 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on June 30, 2009 at $56.52 per share are to be settled in cash upon the Reporting Person's Retirement. F4 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on June 30, 2009 at $56.52 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| June 30, 2009 Filed Jul 2, 2009 19:28 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000082 · edgar.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Stock Fund under the 401(k) Savings Plan Disclosed balance after: 1,130 F2 · security: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (06/30/2009). F2 · price: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (06/30/2009). Read SEC document |
| March 31, 2009 Filed Apr 2, 2009 19:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPhantom Stock Units · Derivative | 50 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000057 · edgar.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,854 Underlying: Common Stock · 50 shares Expires not disclosed F5 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F4 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on March 31, 2009 at $52.82 per share are to be settled in cash upon the Reporting Person's Retirement. F4 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on March 31, 2009 at $52.82 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| March 31, 2009 Filed Apr 2, 2009 19:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 77 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000057 · edgar.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Stock Fund under the 401(k) Savings Plan Disclosed balance after: 1,011 F2 · security: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (03/31/2009). F2 · price: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (03/31/2009). Read SEC document |
| February 13, 2009 Filed Feb 17, 2009 23:30 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 5,999 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000040 · edgar.xml · derivative · entry 6 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 5,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Share Unit, awarded under Issuer's Long-Term Incentive Plan on February 13, 2006, represents a contingent right to receive one share of Company Common Stock. F7 · derivative.expiration_date: Not applicable. Read SEC document |
| February 13, 2009 Filed Feb 17, 2009 23:30 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon | 2,236 | $57.31 | $128,145.16 |
DisclosureSEC source: 0000200406-09-000040 · edgar.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,429 Read SEC document |
| February 13, 2009 Filed Feb 17, 2009 23:30 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon | 5,999 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000040 · edgar.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under Issuer's Dividend Reinvestment Program. Read SEC document |
| February 12, 2009 Filed Feb 17, 2009 23:30 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPhantom Stock Units · Derivative | 1,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000040 · edgar.xml · derivative · entry 5 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,804 Underlying: Common Stock · 1,579 shares Expires not disclosed F5 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F4 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on February 12, 2009 at $56.97 per share are to be settled in cash upon the Reporting Person's Retirement. F4 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on February 12, 2009 at $56.97 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| February 09, 2009 Filed Feb 11, 2009 22:39 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 6,858 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000027 · edgar.xml · derivative · entry 6 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,858 Underlying: Common · 6,858 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one share of Company Common Stock. F8 · derivative.expiration_date: The Restricted Share Units vest three years after date of grant. Read SEC document |
| February 09, 2009 Filed Feb 11, 2009 22:39 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Option (Right to Buy) · Derivative | 82,290 | $0.00 Strike: $58.33 | $0.00 |
DisclosureSEC source: 0000200406-09-000027 · edgar.xml · derivative · entry 5 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,290 Underlying: Common · 82,290 shares Expires 2019-02-08 F6 · security: Awarded under Issuer's Long-Term Incentive Plan. Read SEC document |
| January 30, 2009 Filed Feb 11, 2009 22:39 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 31 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000027 · edgar.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Stock Fund under the 401(k) Savings Plan Disclosed balance after: 934 F2 · price: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (01/30/2009). Read SEC document |
| December 31, 2008 Filed Jan 5, 2009 19:41 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherPhantom Stock Units · Derivative | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000001 · edgar.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,225 Underlying: Common Stock · 33 shares Expires not disclosed F3 · security: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2008 at $58.73 per share are to be settled in cash upon the Reporting Person's Retirement. F4 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F3 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2008 at $58.73 per share are to be settled in cash upon the Reporting Person's Retirement. F3 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2008 at $58.73 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| December 31, 2008 Filed Jan 5, 2009 19:41 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 8 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000001 · edgar.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) and ESOP Savings Plans Disclosed balance after: 936 F2 · security: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plans' most recent reporting date (12/31/2008). F2 · price: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plans' most recent reporting date (12/31/2008). Read SEC document |
| September 30, 2008 Filed Oct 2, 2008 13:46 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherPhantom Stock Units · Derivative | 28 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-08-000135 · edgar.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,192 Underlying: Common Stock · 28 shares Expires not disclosed F3 · security: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on September 30, 2008 at $68.38 per share are to be settled in cash upon the Reporting Person's Retirement. F4 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F3 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on September 30, 2008 at $68.38 per share are to be settled in cash upon the Reporting Person's Retirement. F3 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on September 30, 2008 at $68.38 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| September 30, 2008 Filed Oct 2, 2008 13:46 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 23 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-08-000135 · edgar.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) and ESOP Savings Plans Disclosed balance after: 928 F2 · security: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plans' most recent reporting date (09/30/2008). F2 · price: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plans' most recent reporting date (09/30/2008). Read SEC document |
| June 30, 2008 Filed Jul 1, 2008 22:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherPhantom Stock Units · Derivative | 30 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-08-000102 · edgar.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,164 Underlying: Common Stock · 30 shares Expires not disclosed F3 · security: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on June 30, 2008 at $64.06 per share are to be settled in cash upon the Reporting Person's Retirement. F4 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F3 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on June 30, 2008 at $64.06 per share are to be settled in cash upon the Reporting Person's Retirement. F3 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on June 30, 2008 at $64.06 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| May 30, 2008 Filed Jul 1, 2008 22:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 71 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-08-000102 · edgar.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) and ESOP Savings Plans Disclosed balance after: 905 F2 · security: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plans' most recent reporting date (05/30/2008). F2 · price: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plans' most recent reporting date (05/30/2008). Read SEC document |
| March 31, 2008 Filed Apr 2, 2008 21:06 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherPhantom Stock Units · Derivative | 26 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-08-000066 · edgar.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,134 Underlying: Common Stock · 26 shares Expires not disclosed F3 · security: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on March 31, 2008 at $64.53 per share are to be settled in cash upon the Reporting Person's Retirement. F4 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F3 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on March 31, 2008 at $64.53 per share are to be settled in cash upon the Reporting Person's Retirement. F3 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on March 31, 2008 at $64.53 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| March 31, 2008 Filed Apr 2, 2008 21:06 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 59 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-08-000066 · edgar.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) and ESOP Savings Plans Disclosed balance after: 834 F2 · security: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plans' most recent reporting date (03/31/2008). F2 · price: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plans' most recent reporting date (03/31/2008). Read SEC document |
| February 14, 2008 Filed Feb 15, 2008 21:35 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPhantom Stock Units · Derivative | 1,496 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-08-000047 · edgar.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,108 Underlying: Common Stock · 1,496 shares Expires not disclosed F3 · security: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on February 14, 2008 at $63.13 per share are to be settled in cash upon the Reporting Person's Retirement. F4 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F3 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on February 14, 2008 at $63.13 per share are to be settled in cash upon the Reporting Person's Retirement. F3 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on February 14, 2008 at $63.13 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| February 11, 2008 Filed Feb 13, 2008 22:39 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 6,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-08-000038 · edgar.xml · derivative · entry 5 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one share of Company Common Stock. F7 · derivative.expiration_date: The Restricted Share Units vest three years after date of grant. Read SEC document |
| February 11, 2008 Filed Feb 13, 2008 22:39 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Option (Right to Buy) · Derivative | 72,874 | $0.00 Strike: $61.75 | $0.00 |
DisclosureSEC source: 0000200406-08-000038 · edgar.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,874 Underlying: Common Stock · 72,874 shares Expires 2018-02-10 F5 · security: Awarded under Issuer's Long-Term Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.